Advertisement

Germs, Gels and Genomes. A Personal Recollection of 30 Years in Blood Safety Testing

  • Roger Y. Dodd
Chapter
Part of the Developments in Hematology and Immunology book series (DIHI, volume 37)

Abstract

Thirty years ago, there was but one test to assure the microbiological safety of the blood supply. This was accompanied by a donor questionnaire that focussed on a history of hepatitis, intravenous drug use and international travel. Today, we use 8 to 10 separate tests, designed to detect 12 different infection markers, and the latest version of the uniform donor questionnaire has no less that 32 separate questions (some of which are themselves multi-part), with more waiting in the wings. Over this period, philosophies have changed and cries for increased blood safety have now been replaced by petitions for financial relief to pay for increased blood safety measures. In this chapter, I will retrace some of this history of blood safety, with special reference to test methods. In parallel, I will consider the evolution of decision-making in this area, and will end by questioning the extent to which we, as blood bankers, may have become trapped in our own history.

Keywords

Human Immunodeficiency Virus Type Human Immunodeficiency Virus Infection Acquire Immune Deficiency Syndrome Window Period Nucleic Acid Test 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Barker LF. In: Dodd RY, Barker LF, eds. Infection, Immunity, and Blood Transfusion. New York: Alan R. Liss; 1985; Introduction. p. xix-xxv.Google Scholar
  2. 2.
    Allen JG. The epidemiology of posttransfusion hepatitis. Basic blood and plasma tabulations. Stanford: Commonwealth Fund; 1972. pp. 1–335Google Scholar
  3. 3.
    Krugman S, Giles JP, Hammond J. Infectious hepatitis. Evidence for two distinctive clinical, epidemiological, and immunological types of infection. JAMA 1967; 200: 365–73.PubMedCrossRefGoogle Scholar
  4. 4.
    Tegtmeier GE, Parks LH, Blosser JK, et al. Hepatitis markers in blood donors with a history of hepatitis or jaundice. [Abstract] Transfusion 1991;31, Supplement:64S.Google Scholar
  5. 5.
    Blumberg BS, Alter HJ, Visnich S. A ‘new’ antigen in leukemia sera. JAMA 1965; 191: 541–46.PubMedCrossRefGoogle Scholar
  6. 6.
    Blumberg BS, Gerstley BJS, Hungerford DA, London WT, Sutnick AI. A serum antigen (Australia antigen) in Down’s syndrome, leukemia and hepatitis. Ann Intern Med 1967; 66: 924.PubMedGoogle Scholar
  7. 7.
    Gocke DJ, Greenberg HB, Kavey NB. Correlation of Australia antigen with posttransfusion hepatitis. JAMA 1970; 212: 877–79.PubMedCrossRefGoogle Scholar
  8. 8.
    Ling CM, Overby LR. Prevalence of hepatitis B virus antigen as revealed by direct radioimmune assay with 125-I-antibody. J Immunol 1972; 109: 834–41.PubMedGoogle Scholar
  9. 9.
    Feinstone SM, Kapikian AZ, Purcell RH, Alter HJ, Holland PV. Transfusion-associated hepatitis not due to viral hepatitis type A or B. N Engl J Med 1975; 292: 767–70.PubMedCrossRefGoogle Scholar
  10. 10.
    Alter HJ, Purcell RH, Holland PV, Ailing DW, Koziol DE. Donor transaminase and recipient hepatitis. Impact on blood transfusion services. JAMA 1981;246:630–34.Google Scholar
  11. 11.
    Koziol DE, Holland PV, Alling DW, et al. Antibody to Hepatitis B core antigen as a paradoxical marker for non-A, non-B hepatitis agents in donated blood. Ann Intern Med. 1986; 104: 488–95.PubMedGoogle Scholar
  12. 12.
    Aach RD, Szmuness W, Mosley JW, et al. Serum alanine aminotransferase of donors in relation to the risk of non-A, non-B hepatitis in recipients. The Transfusion-Transmitted Viruses Study. N Engl J Med 1981; 304: 989–94.PubMedCrossRefGoogle Scholar
  13. 13.
    Stevens CE, Aach RD, Hollinger FB, et al. Hepatitis B virus antibody in blood donors and the occurrence of Non-A, non-B hepatitis in transfusion recipients. An analysis of the Transmission-Transmitted Viruses Study. Ann Intern Med. 1984; 101: 733–38.PubMedGoogle Scholar
  14. 14.
    Hombrook MC, Dodd RY, Jacobs P, Friedman LI, Sherman KE. Reducing the incidence of non-A, non-B post-transfusion hepatitis by testing donor blood for alanine aminotransferase. Economic considerations. New Engl J Med 1982; 307: 1315–21.CrossRefGoogle Scholar
  15. 15.
    Curran JW, Lawrence DN, Jaffe H, et al. Acquired immunodeficiency syndrome (AIDS) associated with transfusions. N Engl J Med 1984; 310: 69–75.PubMedCrossRefGoogle Scholar
  16. 16.
    Peterman TA, Jaffe HW, Feorino PM, et al. Transfusion-associated acquired immunodeficiency syndrome in the United States. JAMA 1985; 254: 2913 17Google Scholar
  17. 17.
    Busch MP, Young MJ, Samson SM, Mosley JW, Ward JW, Perkins HA, Transfusion Safety Study Group. Risk of human immunodeficiency virus (HIV) transmission by blood transfusions before the implementation of HIV-1 antibody screening. Transfusion 1991; 31: 4–11.Google Scholar
  18. 18.
    Gallo RC, Salahuddin SZ, Popovic M, et al. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science 1984; 224: 500–03.PubMedCrossRefGoogle Scholar
  19. 19.
    Barre-Sinoussi F, Chermann J-C, Rey F, et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983; 220: 868–71.PubMedCrossRefGoogle Scholar
  20. 20.
    Schorr JB, Berkowitz A, Cumming PD, Katz AJ, Sandler SG. Prevalence of HTLV-III antibody in American blood donors. N Engl J Med 1985;313:38485.Google Scholar
  21. 21.
    Williams AE, Fang CT, Slamon DJ, et al. Seroprevalence and epidemiological correlates of HTLV-1 infection in U.S. blood donors. Science 1988; 240: 643–46.PubMedCrossRefGoogle Scholar
  22. 22.
    Sullivan MT, Williams AE, Fang CT, et al. Transmission of human Tlymphotropic virus types I and II by blood transfusion: A retrospective study of recipients of blood components (1983 through 1988). Arch Intern Med. 1991; 151: 2043–48.PubMedCrossRefGoogle Scholar
  23. 23.
    Choo Q-L, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood borne non-A, non-B viral hepatitis genome. Science 1989; 244: 359–62.PubMedCrossRefGoogle Scholar
  24. 24.
    Kuo G, Choo Q-L, Alter Ill, Gitnick GL, et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 1989; 244: 362–64.PubMedCrossRefGoogle Scholar
  25. 25.
    Alter HJ, Epstein JS, Swenson SG, et al. Prevalence of human immunodeficiency virus type 1 p24 antigen in U.S. blood donors-An assessment of the efficacy of testing in donor screening. N Engl J Med. 1990; 323: 1312–17.PubMedCrossRefGoogle Scholar
  26. 26.
    Petersen LR, Satten G, Dodd RY, et al. Current estimates of the infectious window period and risk of HIV infection from seronegative blood donations. [Abstract] Program and Abstracts: Fifth National Forum on AIDS, Hepatitis, and Other Blood-Borne Diseases 1992; 37.Google Scholar
  27. 27.
    Busch MP, Lee LLL, Satten GA, Henrard DR, et al. Time course of detection of viral and serologic markers preceding human immunodeficiency virus type 1 seroconversion: Implications for screening of blood and tissue donors. Transfusion 1995;35:91–97.Google Scholar
  28. 28.
    Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ. The risk of transfusion-transmitted viral infections. N Engl J.Med. 1996; 334: 1685–90.Google Scholar
  29. 29.
    Murthy KK, Henrard DR, Eichberg JW, Cobb KE, Busch MP, Allain JP, Alter HJ. Redefining the HIV-infectious window period in the chimpanzee model: evidence to suggest that viral nucleic acid testing can prevent blood-borne transmission. Transfusion 1999; 39: 688–93.PubMedCrossRefGoogle Scholar
  30. 30.
    Corash L. Virus inactivation in cellular components. Vox Sang. 1996; 70 (Suppl. 3): 9–16.CrossRefGoogle Scholar
  31. 31.
    Dodd RY, Stramer SL. Indeterminate results in blood donor testing: What you don’t know can hurt you. Transfus Med Rev 2000; 14: 151–60.PubMedCrossRefGoogle Scholar
  32. 32.
    Sarngadharan MG, Popovic M, Bruch L, Schupbach J, Gallo RC. Antibodies reactive with human T-lymphotropic retroviruses (HTLV-III) in the serum of patients with AIDS. Science 1984; 224: 506–08.PubMedCrossRefGoogle Scholar
  33. 33.
    Foster KR, Vecchia P, Repacholi MH. Risk management. Science and the precautionary principle. Science 2000; 288: 979–81.PubMedCrossRefGoogle Scholar
  34. 34.
    Desforges JF, Athari F, Cooper ES, et al. Infectious disease testing for blood transfusions. JAMA 1995; 274: 1374–79.CrossRefGoogle Scholar
  35. 35.
    Orton SL, ARCNET Program, Liu H, et al. Prevalence of circulating T. pallidum in STS+/FTA-ABS+ blood donors. [Abstract] Transfusion 2000; 39:(S)2S.Google Scholar
  36. 36.
    Nahlen BL, Lobel HO, Cannon SE, Campbell CC. Reassessment of blood donor selection criteria for United States travellers to malarious areas. Transfusion 1991; 31: 798–804.PubMedCrossRefGoogle Scholar
  37. 37.
    Dodd RY, Stramer SL, Aberle-Grasse J, Notari E. Risk of hepatitis and retroviral infections among blood donors and introduction of nucleic acid testing (NAT). Dev Biol Stand 2000; 102: 19–27.Google Scholar
  38. 38.
    Ward JW, Holmberg SD, Allen JR, et al. Transmission of human immunodeficiency virus (HIV) by blood transfusions screened as negative for HIV antibody. N.Engl J Med. 1988; 318: 473–78.PubMedCrossRefGoogle Scholar
  39. 39.
    Cumming PD, Wallace EL, Schorr JB, Dodd RY. Exposure of patients to human immunodeficiency virus through the transfusion of blood components that test antibody-negative. N Engl J Med. 1989; 321: 941–46.PubMedCrossRefGoogle Scholar
  40. 40.
    Busch MP, Eble BE, Khayam-Bashi H, et al. Evaluation of screened blood donations for human immunodeficiency virus type 1 infection by culture and DNA amplification of pooled cells. N Engl J Med. 1991; 325: 1–5.PubMedCrossRefGoogle Scholar
  41. 41.
    Nelson ICE, Donahue JG, Munoz A, et al. Transmission of retroviruses from seronegative donors by transfusion during cardiac surgery. A multicenter study of HIV-1 and HTLV-IJII infections. Ann Intern Med. 1992;117:554–59.Google Scholar
  42. 42.
    Petersen LR, Satten GA, Dodd R, et al. HIV Seroconversion Study Group. Duration of time from onset of human immunodeficiency virus type 1 infectiousness to development of detectable antibody. Transfusion 1994;34: 28389.Google Scholar
  43. 43.
    Lackritz EM, Satten GA, Aberle-Grasse J et al. Estimated risk of transmission of the human immunodeficiency virus by screened blood in the United States. N Engl J Med. 1995; 333: 1721–25.PubMedCrossRefGoogle Scholar
  44. 44.
    Alter HJ. You’ll wonder where the yellow went: A 15-year retrospective of posttransfusion hepatitis. In: Moore SB, editor. Transfusion-Transmitted Viral Diseases. Arlington, VA: AABB; 1987; 4:p. 53–86.Google Scholar
  45. 45.
    Donahue JG, Munoz A, Ness PM, et al. The declining risk of post-transfusion hepatitis C virus infection. N Engl J Med. 1992; 327: 369–73.PubMedCrossRefGoogle Scholar
  46. 46.
    Alter, MJ Residual risk of transfusion-associated hepatitis. Bethesda, MD: National Institutes of Health; NIH Consensus Development Conference on Infectious Disease Testing for Blood Transfusions. 1995; 23.Google Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2002

Authors and Affiliations

  • Roger Y. Dodd
    • 1
  1. 1.Transmissible Diseases DepartmentAmerican Red Cross Holland LaboratoryRockvilleUSA

Personalised recommendations